BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 11060826)

  • 1. Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease.
    Sunder-Plassmann G; Winkelmayer WC; Födinger M
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2637-51. PubMed ID: 11060826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12.
    Billion S; Tribout B; Cadet E; Queinnec C; Rochette J; Wheatley P; Bataille P
    Nephrol Dial Transplant; 2002 Mar; 17(3):455-61. PubMed ID: 11865092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease.
    Wrone EM; Zehnder JL; Hornberger JM; McCann LM; Coplon NS; Fortmann SP
    Kidney Int; 2001 Sep; 60(3):1106-13. PubMed ID: 11532106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins.
    Tremblay R; Bonnardeaux A; Geadah D; Busque L; Lebrun M; Ouimet D; Leblanc M
    Kidney Int; 2000 Aug; 58(2):851-8. PubMed ID: 10916110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease.
    Hyndman ME; Manns BJ; Snyder FF; Bridge PJ; Scott-Douglas NW; Fung E; Parsons HG
    Metabolism; 2003 Feb; 52(2):168-72. PubMed ID: 12601627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients.
    Bostom AG; Shemin D; Lapane KL; Nadeau MR; Sutherland P; Chan J; Rozen R; Yoburn D; Jacques PF; Selhub J; Rosenberg IH
    Atherosclerosis; 1996 Jun; 123(1-2):193-202. PubMed ID: 8782850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The C677T MTHFR genotypes influence the efficacy of B9 and B12 vitamins supplementation to lowering plasma total homocysteine in hemodialysis.
    Achour O; Elmtaoua S; Zellama D; Omezzine A; Moussa A; Rejeb J; Boumaiza I; Bouacida L; Rejeb NB; Achour A; Bouslama A
    J Nephrol; 2016 Oct; 29(5):691-8. PubMed ID: 26559681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homocysteine and renal disease.
    van Guldener C; Robinson K
    Semin Thromb Hemost; 2000; 26(3):313-24. PubMed ID: 11011849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The controversy over homocysteine and cardiovascular risk.
    Ueland PM; Refsum H; Beresford SA; Vollset SE
    Am J Clin Nutr; 2000 Aug; 72(2):324-32. PubMed ID: 10919921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supplementation with vitamin B12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease.
    Dierkes J; Domröse U; Ambrosch A; Schneede J; Guttormsen AB; Neumann KH; Luley C
    Metabolism; 1999 May; 48(5):631-5. PubMed ID: 10337865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients].
    Armada E; Pérez Melón C; Otero A; Gayoso P; Rodríguez M; Esteban Morcillo J
    Nefrologia; 2001; 21(2):167-73. PubMed ID: 11464650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M;
    Clin Chem Lab Med; 2003 Nov; 41(11):1392-403. PubMed ID: 14656016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS).
    McQuillan BM; Beilby JP; Nidorf M; Thompson PL; Hung J
    Circulation; 1999 May; 99(18):2383-8. PubMed ID: 10318658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylenetetrahydrofolate reductase genotype, vitamin B12, and folate influence plasma homocysteine in hemodialysis patients.
    Nakamura T; Saionji K; Hiejima Y; Hirayama H; Tago K; Takano H; Tajiri M; Hayashi K; Kawabata M; Funamizu M; Makita Y; Hata A
    Am J Kidney Dis; 2002 May; 39(5):1032-9. PubMed ID: 11979347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients].
    Trimarchi H; Young P; Díaz ML; Schropp J; Forrester M; Freixas E
    Medicina (B Aires); 2005; 65(6):513-7. PubMed ID: 16433478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
    Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy of hyperhomocysteinaemia in patients with thrombophilia.
    O'Donnell J; Perry DJ
    Expert Opin Pharmacother; 2002 Nov; 3(11):1591-8. PubMed ID: 12437493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
    Jamison RL; Hartigan P; Kaufman JS; Goldfarb DS; Warren SR; Guarino PD; Gaziano JM;
    JAMA; 2007 Sep; 298(10):1163-70. PubMed ID: 17848650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety of two vitamin supplement regimens on homocysteine levels in hemodialysis patients. Prospective, randomized clinical trial].
    Sánchez Alvarez JE; Pérez Tamajón L; Hernández D; Alvarez González A; Delgado P; Lorenzo V
    Nefrologia; 2005; 25(3):288-96. PubMed ID: 16053010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients.
    Hauser AC; Hagen W; Rehak PH; Buchmayer H; Födinger M; Papagiannopoulos M; Bieglmayer C; Apsner R; Köller E; Ignatescu M; Hörl WH; Sunder-Plassmann G
    Am J Kidney Dis; 2001 Apr; 37(4):758-65. PubMed ID: 11273876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.